Hims & Hers Health, Inc. (HIMS)
Why Hims & Hers Management Might Be Its Most Valuable Asset
Hims & Hers Health is a telehealth leader with strong revenue growth, innovative personalized solutions, and ambitious global expansion plans. Despite traditional valuation metrics suggesting overvaluation, I see long-term growth potential driven by top management strategic decisions, AI, new products, and international markets. Key risks include high stock-based compensation, regulatory scrutiny around compounded drugs, and intensifying competition from major healthcare players.
Hims & Hers to offer generic semaglutide in Canada starting in 2026
Hims & Hers (NYSE:HIMS) announced plans to expand its digital health and weight loss services to Canada in 2026, coinciding with the first global availability of generic semaglutide. Beginning in January 2026, Canada will become the first country to offer generic versions of semaglutide, a GLP-1 receptor agonist widely used for weight management under brand names such as Wegovy and Ozempic.
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Hims & Hers Health: Unlocking A $6 Billion Future
Hims & Hers grew Q1 2025 revenue by 111% to $586 million, with adjusted EBITDA nearly tripling to $91 million. Nearly 60% of the 2.4 million subscribers now use personalized treatments, boosting retention and average revenue per user to $84. Despite the Novo Nordisk split, the diversified GLP-1 and weight loss portfolio targets $725 million in 2025 specialty revenue.
Health Meets Lifestyle: How Hims & Hers Is Reshaping Everyday Wellness
HIMS is transforming digital wellness with personalized care, over 30 million telehealth consultations, and a Gen Z-aligned platform.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Enhances Healthcare Through AI-Driven Personalization
HIMS taps AI and $870 million in funding to deliver smarter, more personalized healthcare through tech-driven innovation.
Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback
There is always a challenging moment in every investor's favorite stock and portfolio, especially when said businesses are still going through what's known as a “growth spurt,” in which lots of things can go extremely well, but also unexpectedly wrong.
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
Hims & Hers Health, Inc. (HIMS) reached $47.96 at the closing of the latest trading day, reflecting a -3.79% change compared to its last close.
Hims & Hers Health: Buy The Novo Nordisk Drama Dip
The Hims & Hers Health investment thesis remains intact, despite the Novo Nordisk partnership ending, due to not being focused on branded GLP-1s. The company has long-term business targets, including $6.5B in 2030 revenue, are driven by personalized services, global expansion, and not dependent on branded drug deals. The ZAVA acquisition and European expansion offset any short-term disruption, boosting the subscriber base by over 50% and opening new markets.
HIMZ: Buy For Short-Term Gains On Hims & Hers Health, But Be Wary Of The Risks
HIMZ offers 2x leveraged exposure to HIMS, ideal for high-risk, short-term traders seeking amplified volatility, not long-term investors. Recent HIMS volatility, including the Novo Nordisk partnership fallout, creates attractive trading opportunities for nimble investors using HIMZ. HIMS continues to innovate and expand, targeting new markets and launching products, leading to strong growth potential and future catalysts.
Hims & Hers Health (HIMS) Loses 22.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Hims & Hers Health (HIMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
